Sector
TradingOpen
₹2,350Prev. Close
₹2,361Turnover(Lac.)
₹77.85Day's High
₹2,363Day's Low
₹2,35052 Week's High
₹052 Week's Low
₹0Book Value
₹437.96Face Value
₹10Mkt Cap (₹ Cr.)
921.18P/E
40.72EPS
58Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 3.77 | 3.77 | 3.77 | 3.9 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 166.9 | 144.29 | 110.95 | 222.06 |
Net Worth | 170.67 | 148.06 | 114.72 | 225.96 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 70.06 | 109.35 | 123.09 | 143.91 |
yoy growth (%) | -35.93 | -11.15 | -14.46 | -8.75 |
Raw materials | -26.22 | -36.02 | -44.1 | -58.93 |
As % of sales | 37.43 | 32.94 | 35.82 | 40.94 |
Employee costs | -3.35 | -20.84 | -17.38 | -22.9 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 30.75 | 38.76 | 29.04 | 28.85 |
Depreciation | -0.01 | -0.08 | -0.36 | -0.37 |
Tax paid | -12.67 | -10.42 | -11.21 | -11.11 |
Working capital | -110.11 | 38.97 | 12.53 | 14.38 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -35.93 | -11.15 | -14.46 | -8.75 |
Op profit growth | -12.65 | 34.4 | -0.9 | -183.49 |
EBIT growth | -21.21 | 34.37 | 0.53 | -237.31 |
Net profit growth | -36.2 | 58.94 | 0.52 | -225.37 |
Particulars (Rupees in Crores.) | Mar-2015 | Mar-2014 | Dec-2012 | Dec-2011 | Dec-2010 |
---|---|---|---|---|---|
Gross Sales | 217.07 | 269.64 | 215.27 | 214.16 | 190.5 |
Excise Duty | 0 | 0 | 0.25 | 0.36 | 0.3 |
Net Sales | 217.07 | 269.64 | 215.02 | 213.8 | 190.21 |
Other Operating Income | 0 | 0 | 0 | 0.4 | 2.33 |
Other Income | 14.22 | 12.53 | 10 | 9.36 | 5.53 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Adani Enterprises Ltd ADANIENT | 2,338.5 | 105.72 | 2,69,905.16 | 534.59 | 0.05 | 6,156.76 | 189.95 |
Vishal Mega Mart Ltd VMM | 113.2 | 119.16 | 51,038.7 | 129.51 | 0 | 1,392.01 | 12.36 |
Aegis Logistics Ltd AEGISLOG | 827.8 | 61.68 | 29,055.78 | 72.16 | 0.79 | 658.28 | 71.38 |
Redington Ltd REDINGTON | 231.75 | 12.99 | 18,117.62 | 460.56 | 2.68 | 13,094.86 | 50.08 |
Cello World Ltd CELLO | 644.4 | 194.68 | 14,233.83 | 23.01 | 0.22 | 249.83 | 64.86 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
PRAMOD HARI LELE
Director
SAMEER ARUNKUMAR TAMHANE
Director
LATIKA PRAKASH PRADHAN
Director
MURALIDHAR VENKATA KARANAM
Director
RAJESH ASHOK TENDOLKAR
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Fulford India Ltd
Summary
Fulford (India) (FIL), was incorporated in Mar.48 under the name C E Fulford, a wholly owned subsidiary of C E Fulford, UK, (now known as Schering-Plough Holdings, UK). The name of the company was changed to Fulford (India) Mar.91. It became a public limited company in Aug.81. It became a direct subsidiary of Schering-Plough Holdings in Dec.80.The company manufactures ethical pharmaceutical products which include various speciality products in the areas of antibiotics, antifungals, anti-allergies, dermatologicals and corticosteroids. Until 1969, the company manufactured and marketed pharmaceutical consumer products which included cough tablets and herbal ointments under the trade marks PEPS and ZAM-BUK. In 1971, it launched Garamycin, its first ethical pharmaceutical product. It has also introduced a new aminoglycoside (Netromycin), and anti-cancer products like Intron-A and Drogenil. During 1995-96, FIL launched TOP NITRO, a hi-tech product for Cardiac diseases and ETHYOL for cytoprotection.Schering Corporation, US, provides technical assistance, information and product improvements. The company is at present a licensed user of several trade marks owned by Schering Corporation, US, and Plough, US, and is the owner of the Schering logo.The company had launched 2 new products viz. Viraferonpeg,Rebetron in 2000-01.In 2005, The wholly owned subsidiary company Wellnex Pharmaceuticals Private Ltd was amalgamated with the company effect from 1st January 2004.The company has taken v
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.